BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Falcon BL, Chintharlapalli S, Uhlik MT, Pytowski B. Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents. Pharmacol Ther 2016;164:204-25. [PMID: 27288725 DOI: 10.1016/j.pharmthera.2016.06.001] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Ibrahim HA, Awadallah FM, Refaat HM, Amin KM. Molecular docking simulation, synthesis and 3D pharmacophore studies of novel 2-substituted-5-nitro-benzimidazole derivatives as anticancer agents targeting VEGFR-2 and c-Met. Bioorganic Chemistry 2018;77:457-70. [DOI: 10.1016/j.bioorg.2018.01.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
2 Nowicki M, Wierzbowska A, Małachowski R, Robak T, Grzybowska-Izydorczyk O, Pluta A, Szmigielska-Kapłon A. VEGF, ANGPT1, ANGPT2, and MMP-9 expression in the autologous hematopoietic stem cell transplantation and its impact on the time to engraftment. Ann Hematol 2017;96:2103-12. [PMID: 28956132 DOI: 10.1007/s00277-017-3133-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
3 Li M, Li J, Guo X, Pan H, Zhou Q. Absence of HTATIP2 Expression in A549 Lung Adenocarcinoma Cells Promotes Tumor Plasticity in Response to Hypoxic Stress. Cancers (Basel) 2020;12:E1538. [PMID: 32545251 DOI: 10.3390/cancers12061538] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Shi YB, Li J, Lai XN, Jiang R, Zhao RC, Xiong LX. Multifaceted Roles of Caveolin-1 in Lung Cancer: A New Investigation Focused on Tumor Occurrence, Development and Therapy. Cancers (Basel) 2020;12:E291. [PMID: 31991790 DOI: 10.3390/cancers12020291] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
5 Liu W, Lu Y, Chai X, Liu X, Zhu T, Wu X, Fang Y, Liu X, Zhang X. Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases. J Exp Clin Cancer Res 2016;35:183. [PMID: 27887633 DOI: 10.1186/s13046-016-0464-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
6 Behrmann L, Wellbrock J, Fiedler W. Acute Myeloid Leukemia and the Bone Marrow Niche-Take a Closer Look. Front Oncol 2018;8:444. [PMID: 30370251 DOI: 10.3389/fonc.2018.00444] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
7 Park W, Kim J, Choi S, Kim T, Park M, Kim S, You JC, Kim JH, Ha KS, Lee JH, Kwon YG, Kim YM. Human plasminogen-derived N-acetyl-Arg-Leu-Tyr-Glu antagonizes VEGFR-2 to prevent blood-retinal barrier breakdown in diabetic mice. Biomed Pharmacother. 2021;134:111110. [PMID: 33338749 DOI: 10.1016/j.biopha.2020.111110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Mohammadi Najafabadi M, Shamsasenjan K, Akbarzadehlaleh P. The Angiogenic Chemokines Expression Profile of Myeloid Cell Lines Co-Cultured with Bone Marrow-Derived Mesenchymal Stem Cells. Cell J 2018;20:19-24. [PMID: 29308614 DOI: 10.22074/cellj.2018.4924] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Taniguchi H, Yoshino T, Yamaguchi K, Yamazaki K, Nixon AB, Tabernero J, Van Cutsem E, Robling KR, Abada PB, Hozak RR, Siegel R, Fill JA, Wijayawardana S, Walgren RA, Giles B, Jones A, Pitts KR, Drove N, Muro K. Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study. Curr Med Res Opin 2021;:1-10. [PMID: 34229554 DOI: 10.1080/03007995.2021.1940908] [Reference Citation Analysis]
10 Graziani G, Ruffini F, Tentori L, Scimeca M, Dorio AS, Atzori MG, Failla CM, Morea V, Bonanno E, D'Atri S, Lacal PM. Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding. Oncotarget 2016;7:72868-85. [PMID: 27655684 DOI: 10.18632/oncotarget.12108] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
11 Zhang Q, Zheng P, Zhu W. Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016-Present). Molecules 2020;25:E2666. [PMID: 32521825 DOI: 10.3390/molecules25112666] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
12 Pimenta DB, Varela VA, Datoguia TS, Caraciolo VB, Lopes GH, Pereira WO. The Bone Marrow Microenvironment Mechanisms in Acute Myeloid Leukemia. Front Cell Dev Biol 2021;9:764698. [PMID: 34869355 DOI: 10.3389/fcell.2021.764698] [Reference Citation Analysis]
13 Haibe Y, Kreidieh M, El Hajj H, Khalifeh I, Mukherji D, Temraz S, Shamseddine A. Resistance Mechanisms to Anti-angiogenic Therapies in Cancer. Front Oncol 2020;10:221. [PMID: 32175278 DOI: 10.3389/fonc.2020.00221] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 28.5] [Reference Citation Analysis]
14 de Cristo Soares Alves A, Lavayen V, Figueiró F, Dallemole DR, de Fraga Dias A, Cé R, Battastini AMO, Guterres SS, Pohlmann AR. Chitosan-Coated Lipid-Core Nanocapsules Functionalized with Gold-III and Bevacizumab Induced In Vitro Cytotoxicity against C6 Cell Line and In Vivo Potent Antiangiogenic Activity. Pharm Res 2020;37:91. [PMID: 32385723 DOI: 10.1007/s11095-020-02804-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
15 Kordi S, Rahmati-Yamchi M, Asghari Vostakolaei M, Barzegari A, Abdolalizadeh J. Purification of a Novel Anti-VEGFR2 Single Chain Antibody Fragment and Evaluation of Binding Affinity by Surface Plasmon Resonance. Adv Pharm Bull 2019;9:64-9. [PMID: 31011559 DOI: 10.15171/apb.2019.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
16 Frezzetti D, Gallo M, Maiello MR, D'Alessio A, Esposito C, Chicchinelli N, Normanno N, De Luca A. VEGF as a potential target in lung cancer. Expert Opin Ther Targets. 2017;21:959-966. [PMID: 28831824 DOI: 10.1080/14728222.2017.1371137] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 11.0] [Reference Citation Analysis]
17 Lu RM, Chiu CY, Liu IJ, Chang YL, Liu YJ, Wu HC. Novel human Ab against vascular endothelial growth factor receptor 2 shows therapeutic potential for leukemia and prostate cancer. Cancer Sci 2019;110:3773-87. [PMID: 31578782 DOI: 10.1111/cas.14208] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
18 Zhang M, Lu W. Enhanced glioma-targeting and stability of LGICP peptide coupled with stabilized peptide DA7R. Acta Pharm Sin B 2018;8:106-15. [PMID: 29872627 DOI: 10.1016/j.apsb.2017.11.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
19 Kanat O, Ertas H. Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy. World J Clin Oncol 2019; 10(2): 52-61 [PMID: 30815371 DOI: 10.5306/wjco.v10.i2.52] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
20 Gao Y, Zhou S, Pang L, Yang J, Li HJ, Huo X, Qian SY. Celastrol suppresses nitric oxide synthases and the angiogenesis pathway in colorectal cancer. Free Radic Res 2019;53:324-34. [PMID: 30773944 DOI: 10.1080/10715762.2019.1575512] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
21 Zhao D, Huang X, Zhang Z, Ding J, Cui Y, Chen X. Engineered nanomedicines for tumor vasculature blockade therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;13:e1691. [PMID: 33480163 DOI: 10.1002/wnan.1691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther 2020;5:22. [PMID: 32296018 DOI: 10.1038/s41392-020-0116-z] [Cited by in Crossref: 130] [Cited by in F6Publishing: 140] [Article Influence: 65.0] [Reference Citation Analysis]
23 Jászai J, Schmidt MHH. Trends and Challenges in Tumor Anti-Angiogenic Therapies. Cells 2019;8:E1102. [PMID: 31540455 DOI: 10.3390/cells8091102] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 18.7] [Reference Citation Analysis]
24 Yang H, Zhou Y, Wang L, Gu T, Lv M, Sun J, Tu C, He J. The Efficacy of Ramucirumab in the Treatment of Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of RCTs. Gastroenterol Res Pract 2021;2021:8960315. [PMID: 33679971 DOI: 10.1155/2021/8960315] [Reference Citation Analysis]
25 Hsieh HL, Tsai MM. Tumor progression-dependent angiogenesis in gastric cancer and its potential application. World J Gastrointest Oncol 2019; 11(9): 686-704 [PMID: 31558974 DOI: 10.4251/wjgo.v11.i9.686] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
26 Micheli L, Parisio C, Lucarini E, Vona A, Toti A, Pacini A, Mello T, Boccella S, Ricciardi F, Maione S, Graziani G, Lacal PM, Failli P, Ghelardini C, Di Cesare Mannelli L. VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody. J Exp Clin Cancer Res 2021;40:320. [PMID: 34649573 DOI: 10.1186/s13046-021-02127-x] [Reference Citation Analysis]
27 Geng Q, Shen H, Zhu W, Lu Y, Wang M, Jiang H, Li D. Safety and Efficacy of Low-Dosage Apatinib Monotherapy in Advanced Lung Squamous-Cell Carcinoma: A Prospective Cohort Study. Onco Targets Ther 2020;13:11529-35. [PMID: 33204107 DOI: 10.2147/OTT.S277532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Song Y, Tang C, Yin C. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells. Biomaterials 2018;185:117-32. [PMID: 30241030 DOI: 10.1016/j.biomaterials.2018.09.017] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 13.0] [Reference Citation Analysis]
29 Yao HP, Tong XM, Wang MH. Pharmaceutical strategies in the emerging era of antibody-based biotherapeutics for the treatment of cancers overexpressing MET receptor tyrosine kinase. Drug Discov Today 2021;26:106-21. [PMID: 33171292 DOI: 10.1016/j.drudis.2020.11.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Kourti M, Cai J, Jiang W, Westwell AD. Structural Modifications on CORM-3 Lead to Enhanced Anti-angiogenic Properties Against Triple-negative Breast Cancer Cells. Med Chem 2021;17:40-59. [PMID: 31808392 DOI: 10.2174/1573406415666191206102452] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Shan Y, Wang B, Zhang J. New strategies in achieving antiangiogenic effect: Multiplex inhibitors suppressing compensatory activations of RTKs. Med Res Rev 2018;38:1674-705. [DOI: 10.1002/med.21517] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
32 Shimazu K, Inoue M, Sugiyama S, Fukuda K, Yoshida T, Taguchi D, Uehara Y, Kuriyama S, Tanaka M, Miura M, Nanjyo H, Iwabuchi Y, Shibata H. Curcumin analog, GO-Y078, overcomes resistance to tumor angiogenesis inhibitors. Cancer Sci 2018;109:3285-93. [PMID: 30024080 DOI: 10.1111/cas.13741] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
33 Mukherjee A, Madamsetty VS, Paul MK, Mukherjee S. Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer. Int J Mol Sci 2020;21:E455. [PMID: 31936832 DOI: 10.3390/ijms21020455] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
34 Wang Z, Winkler N, Qian B, Groß W, Mehrabi A, Ryschich E. Endothelial capture using antibodies and nanoparticles in human tissues: Antigen identification and liver segment imaging. Acta Biomater 2019;97:474-89. [PMID: 31398471 DOI: 10.1016/j.actbio.2019.08.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
35 Zhao K, Yuan Y, Lin B, Miao Z, Li Z, Guo Q, Lu N. LW-215, a newly synthesized flavonoid, exhibits potent anti-angiogenic activity in vitro and in vivo. Gene 2018;642:533-41. [PMID: 29196258 DOI: 10.1016/j.gene.2017.11.065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
36 Elshaer SL, Mohamed IN, Coucha M, Altantawi S, Eldahshan W, Bartasi ML, Shanab AY, Lorys R, El-Remessy AB. Deletion of TXNIP Mitigates High-Fat Diet-Impaired Angiogenesis and Prevents Inflammation in a Mouse Model of Critical Limb Ischemia. Antioxidants (Basel) 2017;6:E47. [PMID: 28661427 DOI: 10.3390/antiox6030047] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
37 Lowery CD, Blosser W, Dowless M, Renschler M, Perez LV, Stephens J, Pytowski B, Wasserstrom H, Stancato LF, Falcon B. Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy. Oncotarget 2019;10:5523-33. [PMID: 31565186 DOI: 10.18632/oncotarget.27148] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
38 Rojo Arias JE, Englmaier VE, Jászai J. VEGF-Trap Modulates Retinal Inflammation in the Murine Oxygen-Induced Retinopathy (OIR) Model. Biomedicines 2022;10:201. [DOI: 10.3390/biomedicines10020201] [Reference Citation Analysis]
39 Kutryb-Zajac B, Harasim G, Jedrzejewska A, Krol O, Braczko A, Jablonska P, Mierzejewska P, Zielinski J, Slominska EM, Smolenski RT. Macrophage-Derived Adenosine Deaminase 2 Correlates with M2 Macrophage Phenotype in Triple Negative Breast Cancer. Int J Mol Sci 2021;22:3764. [PMID: 33916440 DOI: 10.3390/ijms22073764] [Reference Citation Analysis]
40 Sakamoto Y, Yamagishi S, Tanizawa Y, Tajimi M, Okusaka T, Ojima H. PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay. Jpn J Clin Oncol 2018;48:396-9. [PMID: 29474549 DOI: 10.1093/jjco/hyy011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
41 Alves ACS, Bruinsmann FA, Guterres SS, Pohlmann AR. Organic Nanocarriers for Bevacizumab Delivery: An Overview of Development, Characterization and Applications. Molecules 2021;26:4127. [PMID: 34299401 DOI: 10.3390/molecules26144127] [Reference Citation Analysis]
42 de Vries MR, Parma L, Peters HAB, Schepers A, Hamming JF, Jukema JW, Goumans MJTH, Guo L, Finn AV, Virmani R, Ozaki CK, Quax PHA. Blockade of vascular endothelial growth factor receptor 2 inhibits intraplaque haemorrhage by normalization of plaque neovessels. J Intern Med 2019;285:59-74. [PMID: 30102798 DOI: 10.1111/joim.12821] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
43 Zadorozhna M, Di Gioia S, Conese M, Mangieri D. Neovascularization is a key feature of liver fibrosis progression: anti-angiogenesis as an innovative way of liver fibrosis treatment. Mol Biol Rep 2020;47:2279-88. [PMID: 32040707 DOI: 10.1007/s11033-020-05290-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
44 Yu G, Shen Y, Xu X, Zhong F. Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis. PLoS One 2020;15:e0242982. [PMID: 33253313 DOI: 10.1371/journal.pone.0242982] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
45 Takahashi K, Masuda T, Harada M, Inoue T, Nakamura S, Naito K, Hara H, Shimazawa M. Anti-VEGFR2 Antibody-modified Micelle for Triggered Drug Delivery and Effective Therapy of Choroidal Neovascularization. Curr Neurovasc Res 2019;16:258-65. [PMID: 31258081 DOI: 10.2174/1567202616666190619150956] [Reference Citation Analysis]
46 Montemagno C, Pagès G. Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs. Front Cell Dev Biol 2020;8:584. [PMID: 32775327 DOI: 10.3389/fcell.2020.00584] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
47 Shi Y, Zhu N, Liu C, Wu H, Gui Y, Liao D, Qin L. Wnt5a and its signaling pathway in angiogenesis. Clinica Chimica Acta 2017;471:263-9. [DOI: 10.1016/j.cca.2017.06.017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
48 Zuo S, Dai G, Wang L, Wen Y, Huang Z, Yang W, Ma W, Ren X. Suppression of angiogenesis and tumor growth by recombinant T4 phages displaying extracellular domain of vascular endothelial growth factor receptor 2. Arch Virol 2019;164:69-82. [PMID: 30259141 DOI: 10.1007/s00705-018-4026-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
49 Zarrin B, Zarifi F, Vaseghi G, Javanmard SH. Acquired tumor resistance to antiangiogenic therapy: Mechanisms at a glance. J Res Med Sci 2017;22:117. [PMID: 29184575 DOI: 10.4103/jrms.JRMS_182_17] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
50 Roberts LM, Munson J. Modulating microenvironments for treating glioblastoma. Curr Tissue Microenviron Rep 2020;1:99-111. [PMID: 33134977 DOI: 10.1007/s43152-020-00010-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Hwang K, Yoon JH, Lee JH, Lee S. Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers. Biomedicines 2021;9:39. [PMID: 33466394 DOI: 10.3390/biomedicines9010039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Abdel-Maged AE, Gad AM, Wahdan SA, Azab SS. Efficacy and safety of Ramucirumab and methotrexate co-therapy in rheumatoid arthritis experimental model: Involvement of angiogenic and immunomodulatory signaling. Toxicol Appl Pharmacol 2019;380:114702. [PMID: 31398424 DOI: 10.1016/j.taap.2019.114702] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
53 Singh J, Luqman S, Meena A. Emerging role of phytochemicals in targeting predictive, prognostic, and diagnostic biomarkers of lung cancer. Food Chem Toxicol 2020;144:111592. [PMID: 32702507 DOI: 10.1016/j.fct.2020.111592] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
54 Zeng DX, Wang CG, Lei W, Huang JA, Jiang JH. Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma. Oncotarget 2017;8:66248-53. [PMID: 29029508 DOI: 10.18632/oncotarget.19908] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
55 Rahmanian M, Seyfoori A, Ghasemi M, Shamsi M, Kolahchi AR, Modarres HP, Sanati-Nezhad A, Majidzadeh-A K. In-vitro tumor microenvironment models containing physical and biological barriers for modelling multidrug resistance mechanisms and multidrug delivery strategies. J Control Release 2021;334:164-77. [PMID: 33895200 DOI: 10.1016/j.jconrel.2021.04.024] [Reference Citation Analysis]
56 Kourti M, Westwell A, Jiang W, Cai J. Repurposing old carbon monoxide-releasing molecules towards the anti-angiogenic therapy of triple-negative breast cancer. Oncotarget 2019;10:1132-48. [PMID: 30800223 DOI: 10.18632/oncotarget.26638] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
57 Zhao J, Lu J, Zhou L, Zhao J, Dong Z. Efficacy for lung metastasis induced by the allogeneic bEnd3 vaccine in mice. Hum Vaccin Immunother 2018;14:1294-304. [PMID: 29360423 DOI: 10.1080/21645515.2018.1427532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]